04:26 PM EST, 01/06/2025 (MT Newswires) -- Arcturus Therapeutics ( ARCT ) said Monday it started dosing patients with cystic fibrosis and ornithine transcarbamylase deficiency in phase 2 multiple ascending dose studies in December 2024.

Patients in the phase 2 cystic fibrosis study are expected to get daily treatments of ARCT-032 over a 28-day period, according to the company.

Patients with ornithine transcarbamylase deficiency will receive five intravenous infusions of ARCT-810 over two months and the first participant in the US received 0.5 milligrams per kilogram dose in December.

The company expects phase 2 interim data for both program in H1.

Arcturus shares were up more than 6% in regular trading.